Enhancement of Humoral and Cellular Responses to HBsAg DNA Vaccination by Immunization with Praziquantel Through Inhibition TGF-beta/Smad2,3 Signaling.

Qiang Zou,Yiwei Zhong,Hairui Su,Youmin Kang,Jin,Qiang Liu,Shuang Geng,Gan Zhao,Bin Wang
DOI: https://doi.org/10.1016/j.vaccine.2009.10.101
IF: 4.169
2010-01-01
Vaccine
Abstract:Praziquantel (PZQ), which is used to treat all forms of schistosomiasis, has been shown to induce strong T cell activities and decrease T regulatory cell levels. In our study, we investigated whether PZQ may be used as an adjuvant for a hepatitis B surface antigen (HBsAg) DNA vaccine (pcD-S2) in eliciting strong humoral and cellular responses. Our data demonstrate that PZQ as an adjuvant increased T cell proliferation and an HBsAg-specific antibody response that was characterized by a higher ratio of IgG2a/IgG1. Moreover, a higher level of IFN-γ in CD4+ and CD8+ T cells were elicited. In addition, a significantly antigen-specific cytotoxic T lymphocyte response was also observed. The expression of TGF-β can be induced by HBsAg, while PZQ as an adjuvant can inhibit the expression of TGF-β and TGF-β/Smad2,3 signaling. The frequency of CD4+CD25+Foxp3+ Treg cells was reduced. Importantly, the regulatory function of CD4+CD25+ Treg cells was correspondingly impaired. Together, these results suggest that PZQ can enhance humoral and cellular responses to HBsAg DNA vaccination through inhibition TGF-β/Smad2,3 signaling.
What problem does this paper attempt to address?